RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ADC Therapeutics Stock

ADC Therapeutics ROA 2025

ADC Therapeutics ROA

-0.49

Ticker

ADCT

ISIN

CH0499880968

WKN

A2PSR8

In 2025, ADC Therapeutics's return on assets (ROA) was -0.49, a -27.55% increase from the -0.68 ROA in the previous year.

ADC Therapeutics Aktienanalyse

What does ADC Therapeutics do?

ADC Therapeutics SA is a biopharmaceutical company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of cancer. Founded in 2011, the company is headquartered in Lausanne, Switzerland. ADCs are customized drugs that consist of an antibody and a cytotoxic drug. The antibody is designed to specifically transport the cytotoxic drug to cancer cells and release it there to destroy the cancer cells. ADC Therapeutics uses a proprietary technology platform called Pyrrolobenzodiazepine (PBD) to manufacture ADCs that have high efficacy and improved safety. The company's business model involves developing and commercializing ADCs in various stages of research, clinical development, and market launch, in collaboration with partners from the pharmaceutical industry. ADC Therapeutics focuses on different types of cancer, including solid tumors such as breast cancer, lung cancer, prostate cancer, and colorectal cancer, as well as hematological tumors such as lymphomas and leukemias. The company has several ADC products in clinical development, including Camidanlumab tesirin (Cami) for the treatment of Hodgkin lymphomas and diffuse large B-cell lymphomas, and ADCT-601 for the treatment of solid tumors overexpressing the HORM2 receptor. ADC Therapeutics has also formed partnerships with other companies, such as Genmab, AstraZeneca, Adagene, and BioNTech, to further develop and commercialize its technology and products. The company aims to improve the quality of life for cancer patients worldwide by providing innovative drugs. ADC Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding ADC Therapeutics's Return on Assets (ROA)

ADC Therapeutics's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing ADC Therapeutics's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider ADC Therapeutics's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in ADC Therapeutics’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about ADC Therapeutics stock

What is the Return on Assets (ROA) of ADC Therapeutics this year?

The Return on Assets (ROA) of ADC Therapeutics is -0.49 undefined this year.

What was the ROA of ADC Therapeutics compared to the previous year?

The ROA of ADC Therapeutics has increased by -27.55% compared to the previous year.

What consequences do high ROA have for investors of ADC Therapeutics?

A high ROA is advantageous for investors of ADC Therapeutics, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in ADC Therapeutics?

A low ROA can be unfavorable for investors of ADC Therapeutics as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of ADC Therapeutics affect the company?

An increase in ROA of ADC Therapeutics can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of ADC Therapeutics impact the company?

A reduction in the ROA of ADC Therapeutics can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of ADC Therapeutics?

Some factors that can influence the ROA of ADC Therapeutics include revenue, operating costs, asset structure, and industry average.

Why is the ROA of ADC Therapeutics important for investors?

The ROA of ADC Therapeutics is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can ADC Therapeutics take to improve ROA?

To improve ROA, ADC Therapeutics can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does ADC Therapeutics pay?

Over the past 12 months, ADC Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ADC Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of ADC Therapeutics?

The current dividend yield of ADC Therapeutics is .

When does ADC Therapeutics pay dividends?

ADC Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ADC Therapeutics?

ADC Therapeutics paid dividends every year for the past 0 years.

What is the dividend of ADC Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ADC Therapeutics located?

ADC Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von ADC Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ADC Therapeutics from 7/12/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/12/2025.

When did ADC Therapeutics pay the last dividend?

The last dividend was paid out on 7/12/2025.

What was the dividend of ADC Therapeutics in the year 2024?

In the year 2024, ADC Therapeutics distributed 0 USD as dividends.

In which currency does ADC Therapeutics pay out the dividend?

The dividends of ADC Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ADC Therapeutics

Our stock analysis for ADC Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ADC Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.